SECsense Logo

AC Immune SA December 2024 Report: Leadership Changes & Strategic Appointments

$ACIU
Form 6-K
Filed on: 2024-12-18
Source
AC Immune SA December 2024 Report: Leadership Changes & Strategic Appointments

Key Information Extracted from the Financial Report (Form 6-K)

  1. Company Details:
  • Name: AC Immune SA
  • Address: EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.
  • Commission File Number: 001-37891.
  1. Reporting Period:
  • Date: For the month of December 2024.
  1. Executive Appointments:
  • Effective January 1, 2025:
    • Mr. Mark Danton is promoted to Executive Vice President (AI/IS).
    • Background: Joined AC Immune in 2019 from Nestlé; has extensive experience in IS, cybersecurity, and digital technology.
    • Dr. Günther Staffler, PhD, is promoted to Senior Vice President of Immunotherapy.
    • Background: Joined AC Immune in 2021 from Affiris; has a PhD in Immunology.
    • Dr. Francesca Capotosti, PhD, is promoted to Vice President of Research.
    • Background: Joined AC Immune in 2013; has a PhD in Life Sciences and has worked on significant therapeutic programs.
  1. Management Changes:
  • Dr. Madiha Derouazi, PhD, the current Chief Scientific Officer, will leave the company at the end of December 2024 by mutual consent. The company expresses gratitude for her contributions.
  1. Incorporation by Reference:
  • This report is to be incorporated by reference into various registration statements on Form F-3 and Form S-8 associated with AC Immune SA.
  1. Signatures:
  • Signed by:
    • Andrea Pfeifer, Chief Executive Officer.
    • Christopher Roberts, Chief Financial Officer.
  • Date of Report: December 18, 2024.

Insights:

  • The appointments reflect AC Immune's strategic focus on integrating AI and digital technologies into its operations, particularly in research and development.
  • The transition in leadership roles suggests a proactive approach to succession planning and organizational optimization, which may enhance the company's innovation and responsiveness in the biotechnology sector.
  • The departure of Dr. Derouazi indicates a significant change in the scientific leadership, which could impact ongoing and future research projects.